Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis  Dr Danish Saleheen, PhD,

Slides:



Advertisements
Similar presentations
Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)
Advertisements

The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis  Dr Michael Roerecke, PhD, Prof Janusz Kaczorowski,
Kerry-Anne Rye, Kwok Leung Ong  The Lancet Diabetes & Endocrinology 
Effect of a bereavement support group on female adolescents' psychological health: a randomised controlled trial in South Africa  Prof Tonya Renee Thurman,
Volume 390, Issue 10089, Pages (July 2017)
Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysis    The Lancet Diabetes &
Total and cause-specific mortality before and after the onset of the Greek economic crisis: an interrupted time-series analysis  Ioannis Laliotis, PhD,
Demographic and practice factors predicting repeated non-attendance in primary care: a national retrospective cohort analysis  David A Ellis, PhD, Ross.
The commercial determinants of health
Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study  Dr Danish Saleheen, PhD,
Contribution of alcohol use disorders to the burden of dementia in France 2008–13: a nationwide retrospective cohort study  Michaël Schwarzinger, MD,
Helen Cox, Mark P Nicol  The Lancet Infectious Diseases 
Meta-analysis of randomised controlled trials
Associations of ambient coarse particulate matter, nitrogen dioxide, and carbon monoxide with the risk of kidney disease: a cohort study  Benjamin Bowe,
Volume 389, Issue 10076, Pages (April 2017)
Residential greenness and prevalence of major depressive disorders: a cross-sectional, observational, associational study of 94 879 adult UK Biobank participants 
Assessment of progress towards universal health coverage for people with disabilities in Afghanistan: a multilevel analysis of repeated cross-sectional.
Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysis    The Lancet Diabetes &
Volume 390, Issue 10092, Pages (July 2017)
Do air quality alerts benefit public health? New evidence from Canada
Gender myths in global health
Volume 389, Issue 10071, Pages (February 2017)
Prof Seena Fazel, MD, Taanvi Ramesh, MSc, Prof Keith Hawton, FMedSci 
Volume 390, Issue 10092, Pages (July 2017)
Volume 392, Issue 10141, Pages (July 2018)
The effect of explosive remnants of war on global public health: a systematic mixed- studies review using narrative synthesis  Alexandra Frost, MSc, Prof.
Arnaud Chiolero  The Lancet Public Health 
Volume 379, Issue 9822, Pages (March 2012)
Kerry-Anne Rye, Kwok Leung Ong  The Lancet Diabetes & Endocrinology 
Volume 4, Issue 6, Pages (June 2017)
Low-level lead exposure and mortality in US adults: a population-based cohort study  Prof Bruce P Lanphear, MD, Stephen Rauch, MPH, Peggy Auinger, MS,
Volume 5, Issue 11, Pages (November 2018)
Sherif M Abdalla, Robert Bortolussi, Noni E MacDonald 
Volume 392, Issue 10160, Pages (November 2018)
The effect of multiple adverse childhood experiences on health: a systematic review and meta-analysis  Prof Karen Hughes, PhD, Prof Mark A Bellis, DSc,
Trajectories of cardiometabolic risk factors before diagnosis of three subtypes of type 2 diabetes: a post-hoc analysis of the longitudinal Whitehall.
Risk of poor development in young children in low-income and middle-income countries: an estimation and analysis at the global, regional, and country.
Effect of a bereavement support group on female adolescents' psychological health: a randomised controlled trial in South Africa  Prof Tonya Renee Thurman,
Volume 390, Issue 10089, Pages (July 2017)
Tobacco use and second-hand smoke exposure in young adolescents aged 12–15 years: data from 68 low-income and middle-income countries  Prof Bo Xi, PhD,
Volume 393, Issue 10172, Pages (February 2019)
Volume 392, Issue 10163, Pages (December 2018)
Effect of a workplace-based group training programme combined with financial incentives on smoking cessation: a cluster-randomised controlled trial  Floor.
The growth and strategic functioning of One Health networks: a systematic analysis  Mishal S Khan, PhD, Peregrine Rothman-Ostrow, MSc, Julia Spencer, MSc,
Effective interventions for unintentional injuries: a systematic review and mortality impact assessment among the poorest billion  Andres I Vecino-Ortiz,
Volume 379, Issue 9822, Pages (March 2012)
Volume 379, Issue 9822, Pages (March 2012)
Muh Geot Wong, Vlado Perkovic  The Lancet Diabetes & Endocrinology 
Thank you to our diverse (but not diverse enough) reviewers
Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial  Dr David Preiss, PhD, Suzanne M Lloyd,
Matthieu J Guitton  The Lancet Planetary Health 
Spatial lifecourse epidemiology
Buyun Liu, Yangbo Sun, Wei Bao  The Lancet Planetary Health 
The Lancet Diabetes & Endocrinology
Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28.
Integrating an early childhood development programme into Bangladeshi primary health-care services: an open-label, cluster-randomised controlled trial 
Recurrence after low-dose radioiodine ablation and recombinant human thyroid- stimulating hormone for differentiated thyroid cancer (HiLo): long-term results.
Reducing the cardiovascular disease burden for people of all ages in the Americas region: analysis of mortality data, 2000–15  Prof Peter Lloyd-Sherlock,
Improving management of neonatal infections
Population attributable fractions for risk factors for dementia in low-income and middle- income countries: an analysis using cross-sectional survey data 
Jeffrey T Howard, Alexis R Santos-Lozada  The Lancet Planetary Health 
Deriving a practical framework for the evaluation of health apps
Volume 6, Issue 8, Pages (August 2019)
Volume 6, Issue 7, Pages (July 2019)
Volume 5, Issue 6, Pages (June 2018)
The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis  Dr Michael Roerecke, PhD, Prof Janusz Kaczorowski,
Institutional challenges to achieving health equity in Ecuador
Sickle cell disease: a new era
Trends in temperature-related age-specific and sex-specific mortality from cardiovascular diseases in Spain: a national time-series analysis  Hicham Achebak,
Volume 6, Issue 7, Pages (July 2019)
Presentation transcript:

Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis  Dr Danish Saleheen, PhD, Philip C Haycock, PhD, Wei Zhao, MSc, Asif Rasheed, MBBS, Adam Taleb, MD, Atif Imran, MBBS, Shahid Abbas, MBBS, Faisal Majeed, MBSS, Saba Akhtar, MBBS, Prof Nadeem Qamar, MBBS, Prof Khan Shah Zaman, MBBS, Prof Zia Yaqoob, MBBS, Tahir Saghir, MBBS, Prof Syed Nadeem Hasan Rizvi, MBBS, Anis Memon, MBBS, Prof Nadeem Hayyat Mallick, MBBS, Prof Mohammad Ishaq, MBBS, Prof Syed Zahed Rasheed, MBBS, Prof Fazal-ur-Rehman Memon, MBBS, Prof Khalid Mahmood, MBBS, Prof Naveeduddin Ahmed, MBBS, Prof Philippe Frossard, DSc, Prof Sotirios Tsimikas, MD, Prof Joseph L Witztum, MD, Prof Santica Marcovina, PhD, Manjinder Sandhu, PhD, Prof Daniel J Rader, MD, Prof John Danesh, FMedSci  The Lancet Diabetes & Endocrinology  Volume 5, Issue 7, Pages 524-533 (July 2017) DOI: 10.1016/S2213-8587(17)30088-8 Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license Terms and Conditions

Figure 1 Overview of analyses Analysis 1: ORs for myocardial infarction with measured values of LPA KIV2 repeats and lipoprotein(a) concentration, adjusted for each other. Analysis 2: Genome-wide association analyses of apolipoprotein(a) protein isoform size and lipoprotein(a) concentration and identification of variants that are exclusively associated with either apolipoprotein(a) protein isoform size or lipoprotein(a) concentration. Analysis 3: Test for causality by comparison of ORs for coronary heart disease associated with either LPA KIV2 repeats or lipoprotein(a) concentration with equivalent differences produced by their trait-specific genetic variants. Analysis 4: Study of soluble OxPL-apoB concentrations in relation to genome-wide genotypes. KIV2=kringle IV type 2. OR=odd ratio. OxPL-apoB=oxidised phospholipid on apolipoprotein B100. *Data only used in genetic analyses. †Data used in mendelian randomisation analyses. The Lancet Diabetes & Endocrinology 2017 5, 524-533DOI: (10.1016/S2213-8587(17)30088-8) Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license Terms and Conditions

Figure 2 Association of variants specifically associated with apolipoprotein(a) isoform size and lipoprotein(a) concentration with various factors in PROMIS Bars are 95% CIs. LPA=lipoprotein(a) gene. KIV2=kringle IV type 2. eGFR=estimated glomerular filtration rate. LpPLA2=lipoprotein-associated phospholipase A2. CFH=complement factor H. MDA-LDL=malondialdehyde-modified LDL. CXCL12=C-X-C motif chemokine 12. FGF21=fibroblast growth factor 21. ICAM=intercellular adhesion molecule 1. VCAM=vascular cell adhesion molecule. MMP9=matrix metallopeptidase 9. CRP=C-reactive protein. VEGF=vascular endothelial growth factor. RAGE=receptor for advanced glycation end products. NrCAM=neural cell adhesion molecule. The Lancet Diabetes & Endocrinology 2017 5, 524-533DOI: (10.1016/S2213-8587(17)30088-8) Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license Terms and Conditions

Figure 3 Mutually adjusted association of LPA KIV2 repeats and lipoprotein(a) concentration with coronary heart disease in PROMIS Bars are 95% CIs. (A) Association of LPA KIV2 repeats with coronary heart disease risk. (B) Association of lipoprotein(a) with coronary heart disease risk. KIV2=kringle IV type 2. OR=odds ratio. The Lancet Diabetes & Endocrinology 2017 5, 524-533DOI: (10.1016/S2213-8587(17)30088-8) Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license Terms and Conditions

Figure 4 Phenotypic and genotypic assessment of apolipoprotein(a) isoform size and lipoprotein(a) concentration in coronary heart disease (A) OR for coronary heart disease per 1-SD increment in LPA KIV2 repeats. (B) OR for coronary heart disease per 1-SD increment in lipoprotein(a) concentration. Phenotypic associations were computed in PROMIS and genetic associations were computed using data from the CARDIoGRAMplusC4D consortium. KIV2=kringle IV type 2. OR=odds ratio. The Lancet Diabetes & Endocrinology 2017 5, 524-533DOI: (10.1016/S2213-8587(17)30088-8) Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license Terms and Conditions

Figure 5 Association of rs7770628 with OxPL-apoB after adjustment for KIV2 repeats and log-lipoprotein(a) concentration in PROMIS Bars are 95% CIs. KIV2=kringle IV type 2. OxPL-apoB=oxidised phospholipid on apolipoprotein B100. The Lancet Diabetes & Endocrinology 2017 5, 524-533DOI: (10.1016/S2213-8587(17)30088-8) Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license Terms and Conditions